FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage 2B/C melanoma in patients 12 years and older.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


Energy and Commerce Committee Health Subcommittee Ranking Member Rep. Anna G. Eshoo (D-CA), Ranking Member Rep. Frank Pallone, Jr. (D-NJ), and Oversight and Investigations Subcommittee Ranking Member Rep. Kathy Castor (D-FL) wrote to FDA Commissioner Robert M. Califf to urge the agency to move forward with guidance to improve the diversity of populations represented in clinical trials.